Mesoblast Limited
No trades
No trades
Price target
4.270.000.00%
The 5 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 6 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of MSB is 2.15 AUD — it has decreased by −0.92% in the past 24 hours. Watch Mesoblast Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange Mesoblast Limited stocks are traded under the ticker MSB.
MSB stock has fallen by −9.66% compared to the previous week, the month change is a −10.42% fall, over the last year Mesoblast Limited has showed a −8.90% decrease.
We've gathered analysts' opinions on Mesoblast Limited future price: according to them, MSB price has a max estimate of 5.46 AUD and a min estimate of 2.90 AUD. Watch MSB chart and read a more detailed Mesoblast Limited stock forecast: see what analysts think of Mesoblast Limited and suggest that you do with its stocks.
MSB stock is 2.11% volatile and has beta coefficient of 1.07. Track Mesoblast Limited stock price on the chart and check out the list of the most volatile stocks — is Mesoblast Limited there?
Today Mesoblast Limited has the market capitalization of 2.82 B, it has decreased by −1.66% over the last week.
Yes, you can track Mesoblast Limited financials in yearly and quarterly reports right on TradingView.
Mesoblast Limited is going to release the next earnings report on Mar 4, 2027. Keep track of upcoming events with our Earnings Calendar.
MSB earnings for the last half-year are −0.02 AUD per share, whereas the estimation was −0.02 AUD, resulting in a −23.22% surprise. The estimated earnings for the next half-year are −0.02 AUD per share. See more details about Mesoblast Limited earnings.
Mesoblast Limited revenue for the last half-year amounts to 99.67 M AUD, despite the estimated figure of 106.91 M AUD. In the next half-year revenue is expected to reach 122.89 M AUD.
MSB net income for the last half-year is −24.68 M AUD, while the previous report showed −61.29 M AUD of net income which accounts for 0.00% change. Track more Mesoblast Limited financial stats to get the full picture.
No, MSB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 12, 2026, the company has 108 employees. See our rating of the largest employees — is Mesoblast Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mesoblast Limited EBITDA is −63.50 M AUD, and current EBITDA margin is −35.50%. See more stats in Mesoblast Limited financial statements.
Like other stocks, MSB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mesoblast Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mesoblast Limited technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mesoblast Limited stock shows the buy signal. See more of Mesoblast Limited technicals for a more comprehensive analysis.